Substance / Medication

Doxorubicin

Overview

Active Ingredient
doxorubicin
RxNorm CUI
3639

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

13 trials linked to this intervention

13
Total Trials
12
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Traditional Chinese medicine protects against doxorubicin cardiotoxicity via epigenetic modification and beyond.
Zhou Jingquan, Liu Huan, Jiang Feng et al. · Phytomedicine · 2025
PMID: 40602291Meta-Analysis
Curative Treatment of Pediatric Hodgkin Lymphoma With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Consolidation Radiotherapy: A Systematic Review and Suggested Recommendations.
Hernández-Benítez Josué, López-Azcarraga Alejandra, Flerlage Jamie E et al. · JCO Glob Oncol · 2025
PMID: 40570263Meta-Analysis
A narrative review of metabolomics approaches in identifying biomarkers of doxorubicin-induced cardiotoxicity.
Singh Amarnath, Bakhtyar Maham, Jun Se-Ran et al. · Metabolomics · 2025
PMID: 40381141Meta-AnalysisFull text (PMC)
Effects of Physical Exercise and the use of Doxorubicin on Cardiac Function in Rodents: A Systematic Review and Meta-Analysis.
Linhares Bruno Gama, Linhares Diego Gama, de Souza Vale Rodrigo Gomes · Curr Cardiol Rev · 2025
PMID: 39931849Meta-AnalysisFull text (PMC)
The effect of flavonoids on the doxorubicin efficacy in cancer treatment.
Asnaashari Solmaz, Amjad Elham, Sokouti Babak · Naunyn Schmiedebergs Arch Pharmacol · 2025
PMID: 40455233Meta-Analysis
The Role of mTOR in the Doxorubicin-Induced Cardiotoxicity: A Systematic Review.
Shackebaei Dareuosh, Hesari Mahvash, Gorgani Sara et al. · Cell Biochem Biophys · 2025
PMID: 39102090Meta-Analysis
Exploring the effects of doxorubicin on survival rates in glioma patients: a comprehensive systematic review.
Mahboubi Elyar, Mondanizadeh Mahdieh, Almasi-Hashiani Amir et al. · Eur J Med Res · 2025
PMID: 40437615Meta-AnalysisFull text (PMC)
Synergistic effects of cold atmospheric plasma and doxorubicin on melanoma: A systematic review and meta-analysis.
Rostami Zeinab, Alizadeh-Navaei Reza, Golpoor Monireh et al. · Sci Rep · 2025
PMID: 40050300Meta-AnalysisFull text (PMC)
Impact of Doxorubicin on Cardiac Function in Dogs: Ejection Fraction Changes and Heart Failure Risk.
Herrera Gustavo Cavinato, Soldi Luiz Ricardo, Oliveira Leandro Machado et al. · Vet Med Sci · 2025
PMID: 40853202Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Doxorubicin (substance)
SNOMED CT
372817009
UMLS CUI
C0013089
RxNorm CUI
3639

Clinical Data

This intervention maps to 13 entities in the Healos knowledge graph.

13
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
13
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.